Full text is available at the source.
Abstract
The prevalence of anemia at delivery was similar for women receiving sulfadoxine-pyrimethamine (SP) and those receiving either amodiaquine (AQ) or a combination of AQ and SP (SPAQ).
- Anemia prevalence at delivery was defined as a hemoglobin concentration of less than 11.0 g/dL.
- No significant difference was observed in the rates of low birth weight between the SP, AQ, and SPAQ groups.
- Women who received AQ or SPAQ reported a higher incidence of adverse events compared to those who received SP.
- The overall effects of AQ and SPAQ on maternal anemia and low birth weight were comparable to those of SP.
- The high frequency of adverse events associated with AQ may limit its usefulness as an alternative to SP for intermittent preventive treatment in pregnancy in Ghana.
Simplified